News

Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease
Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...
PharmaTimes6d
Amgen’s Tepezza granted marketing authorisation in the UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...
The Pharma Letter6d
MHRA approves Amgen’s Tepezza for TED
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...
National Health Executive5d
UK first treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...
What the Options Market Tells Us About Amgen
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...
Amgen outlook revised to stable at S&P, debt reduction continues
The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...
Le Lézard6d
New Executive Management Board at Bender - the world's leading provider of solutions that make electrical infrastructures smart and safer
Bender Industries GmbH & Co. KG (Bender) appoints Michael Breuer as CEO and Nicole Bender as CFO. Heinz Nowicki and Dr. Sven Hartung have left the company. - Picture is available at AP - As of 1 May ...